Analyst Price Targets — CARM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 11, 2024 6:33 am | Justin Zelin | BTIG | $6.00 | $1.91 | StreetInsider | BTIG Starts Carisma Therapeutics Inc (CARM) at Buy |
Latest News for CARM
PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): Three growth engines: NRI up 8.8% to €403.1 million Organic growth: adding 3.5% to net rental income, outpacing indexation by 110 basis points. Investment growth: adding 5.3% to net rental income; successful integration of Galimmo Innovation growth: recurring earnings contribution of €27 million, growing by 14% Operational excellence confirmed, all KPIs…
Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 14.0% of Context
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CARM.
U.S. House Trading
No House trades found for CARM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.